

## Epigenetics – Are We There Yet? Building on the Foundations of DNMT and HDAC Inhibitors

**Moderator:** Jeff Bockman, PhD, Vice President, Defined Health


### **Panelists:**

- James S.J. Manuso, PhD, President & Chief Executive Officer, Astex Pharmaceuticals
- Keith E. Dionne, PhD, President and Chief Executive Officer, Constellation Pharmaceuticals
- Robert J. Gould, PhD, Chief Executive Officer, Epizyme, Inc.

The logo features the words "CANCER" and "PROGRESS" in a bold, black, sans-serif font. "CANCER" is positioned above "PROGRESS". Below "PROGRESS" is the tagline "by Defined Health" in a smaller, italicized, black font. The text is overlaid on a large, light blue, tilted oval shape.


**CANCER**  
**PROGRESS**  
*by Defined Health*

# Epigenetic Drug Development Has Accelerated Over Past Few Years








Cell, Vol 150, Issue 1, 6 July 2012, Pages 12–27

# Targets Are Proliferating as We Expand Our Knowledge into Readers, Writers, Erasers & Regulators



Nat Med. 2011 Mar;17(3):330-

# Targets Are Proliferating as We Expand Our Knowledge into Readers, Writers, Erasers & Regulators



Cell, Vol 150, Issue 1, 6 July 2012, Pages 12-27

# Epigenetics – Are We There Yet? Building on the Foundations of DNMT and HDAC Inhibitors

**Moderator:** Jeff Bockman, PhD, Vice President, Defined Health

## **Panelists:**

- James S.J. Manuso, PhD, President & Chief Executive Officer, Astex Pharmaceuticals
- Keith E. Dionne, PhD, President and Chief Executive Officer, Constellation Pharmaceuticals
- Robert J. Gould, PhD, Chief Executive Officer, Epizyme, Inc.

The logo features the words "CANCER" and "PROGRESS" in a bold, black, sans-serif font. "CANCER" is positioned above "PROGRESS". Below "PROGRESS" is the tagline "by Defined Health" in a smaller, italicized, black font. The entire text is overlaid on a large, light blue, tilted oval shape.

**CANCER**  
**PROGRESS**  
*by Defined Health*